Glioblastoma with PNET-like components has a higher frequency of isocitrate dehydrogenase 1 (IDH1) mutation and likely a better prognosis than primary glioblastoma

International Journal of Clinical and Experimental Pathology

Volumn 4, Issue 7, 2011, Pages 651-660

  Song, Xianyuan ^a   Allen, R Andrew ^b   Dunn, S Terence ^b   Fung, Kar Ming ^b   Farmer, Peter ^c   Gandhi, Shital ^d   Ranjan, Tulika ^d   Demopoulos, Alexis ^e   Symons, Marc ^f   Schulder, Michae ^d   Li, Jian Yi ^a,c  

^a HARTFORD HOSPITAL   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^d NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

Cd56; Diffusion weighted imaging (DWI); Glioblastoma; Glioblastoma with PNET like components; Isocitrate dehydrogenase 1 (IDH1); Vimentin

Indexed keywords

CD56 ANTIGEN; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; NCAM1 PROTEIN, HUMAN; PROTEIN P53; TP53 PROTEIN, HUMAN; VIMENTIN;

ADULT; AGED; ARTICLE; BRAIN TUMOR; CHEMISTRY; DIFFUSION WEIGHTED IMAGING; ENZYMOLOGY; FEMALE; GENETICS; GLIOBLASTOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MIXED TUMOR; MUTATION; NEUROECTODERM TUMOR; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROGNOSIS; SURVIVAL; SURVIVAL RATE; TIME;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD56; BRAIN NEOPLASMS; DIFFUSION MAGNETIC RESONANCE IMAGING; DNA MUTATIONAL ANALYSIS; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; MUTATION; NEOPLASMS, COMPLEX AND MIXED; NEUROECTODERMAL TUMORS, PRIMITIVE; PROGNOSIS; SURVIVAL ANALYSIS; SURVIVAL RATE; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53; VIMENTIN;

EID: 84862918595     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Kleihues P, Burger PC, Aldape KD, Brat DJ, Biernat W, Bigner DD, Nakazato Y, Plate KH, Giangaspero F, von Deimling A, Ohgaki H, and Cavenee WK. Glioblastoma 2007; 33-46.
2. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, and Bigner DD. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360: 765-773.
3. Yen KE, Bittinger MA, Su SM, and Fantin VR. Cancer-associated IDH mutations: biomarker and therapeutic opportunities. Oncogene 2010; 29: 6409-6417.
4. Setty P, Hammes J, Rothamel T, Vladimirova V, Kramm CM, Pietsch T, and Waha A. A pyrosequencing-based assay for the rapid detection of IDH1 mutations in clinical samples. J Mol Diagn 2010; 12: 750-756.
5. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, and von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 2008; 116: 597-602.
6. Kouyialis AT, Boviatsis EI, Karampelas IK, Korfias S, Korkolopoulou P, and Sakas DE. Primitive supratentorial neuroectodermal tumor in an adult. J Clin Neurosci 2005; 12: 492-495.
7. Ohba S, Yoshida K, Hirose Y, Ikeda E, and Kawase T. A supratentorial primitive neuroectodermal tumor in an adult: a case report and review of the literature. J Neurooncol 2008; 86: 217-224.
8. Shingu T, Kagawa T, Kimura Y, Takada D, Moritake K, and Hoshii Y. Supratentorial primitive neuroectodermal tumor in an aged patient-case report. Neurol Med Chir (Tokyo) 2005; 45: 530-535.
9. Erdem E, Zimmerman RA, Haselgrove JC, Bilaniuk LT, and Hunter JV. Diffusion-weighted imaging and fluid attenuated inversion recovery imaging in the evaluation of primitive neuroectodermal tumors. Neuroradiology 2001; 43: 927-933.
10. Gessi M, Setty P, Bisceglia M, Zur MA, Lauriola L, Waha A, Giangaspero F, and Pietsch T. Supratentorial primitive neuroectodermal tumors of the central nervous system in adults: molecular and histopathologic analysis of 12 cases. Am J Surg Pathol 2011; 35: 573-582.
11. Hayden JT, Fruhwald MC, Hasselblatt M, Ellison DW, Bailey S, and Clifford SC. Frequent IDH1 mutations in supratentorial primitive neuroectodermal tumors (sPNET) of adults but not children. Cell Cycle 2009; 8: 1806-1807.
12. Perry A, Miller CR, Gujrati M, Scheithauer BW, Zambrano SC, Jost SC, Raghavan R, Qian J, Cochran EJ, Huse JT, Holland EC, Burger PC, and Rosenblum MK. Malignant gliomas with primitive neuroectodermal tumor-like components: a clinicopathologic and genetic study of 53 cases. Brain Pathol 2009; 19: 81-90.
13. McLendon RE, Bentley RC, Parisi JE, Tien RD, Harrison JC, Tarbell NJ, Billitt AL, Gualtieri RJ, and Friedman HS. Malignant supratentorial glial-neuronal neoplasms: report of two cases and review of the literature. Arch Pathol Lab Med 1997; 121: 485-492.
14. Wharton SB, Whittle IR, Collie DA, Bell HS, and Ironside JW. Gliosarcoma with areas of primitive neuroepithelial differentiation and extracranial metastasis. Clin Neuropathol 2001; 20: 212-218.
15. McLendon RE and Provenzale J. Glioneuronal tumors of the central nervous system. Brain Tumor Pathol 2002; 19: 51-58.
16. Ishizawa K, Kan-nuki S, Kumagai H, Komori T, and Hirose T. Lipomatous primitive neuroectodermal tumor with a glioblastoma component: a case report. Acta Neuropathol 2002; 103: 193-198.
17. Kepes JJ. Gliosarcoma with areas of primitive neuroepithelial differentiation and extracranial metastasis. Clin Neuropathol 2002; 21: 193-195.
18. Dulai MS, Bosanko CM, Wang AM, Horoupian DS, Boodin S, Chen PY, and Wilson JD. Mixed cystic gliosarcoma and primitive neuroectodermal tumor: a case report. Clin Neuropathol 2004; 23: 218-222.
19. Shibahara J and Fukayama M. Secondary glioblastoma with advanced neuronal immunophenotype. Virchows Arch 2005; 447: 665-668.
20. Kaplan KJ and Perry A. Gliosarcoma with primitive neuroectodermal differentiation: case report and review of the literature. J Neurooncol 2007; 83: 313-318.
21. Balik V, Mirossay P, Bohus P, Sulla I, Mirossay L, and Sarissky M. Flow cytometry analysis of neural differentiation markers expression in human glioblastomas may predict their response to chemotherapy. Cell Mol Neurobiol 2009; 29: 845-858.
22. Fukuda T, Yasumichi K, and Suzuki T. Immunohistochemistry of gliosarcoma with liposarcomatous differentiation. Pathol Int 2008; 58: 396-401.
23. Etzell JE, Keet C, McDonald W, and Banerjee A. Medulloblastoma simulating acute myeloid leukemia: case report with a review of "myeloid antigen" expression in nonhematopoietic tissues and tumors. J Pediatr Hematol Oncol 2006; 28: 703-710.
24. Katoh M, Aida T, Sugimoto S, Suwamura Y, Abe H, Isu T, Kaneko S, Mitsumori K, Kojima H, Nakamura N, and. Immunohistochemical analysis of giant cell glioblastoma. Pathol Int 1995; 45: 275-282.
25. Felsberg J, Wolter M, Seul H, Friedensdorf B, Goppert M, Sabel MC, and Reifenberger G. Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing. Acta Neuropathol 2010; 119: 501-507.
26. Hayashi T, Kushida Y, Kadota K, Katsuki N, Bando K, Miyai Y, Funamoto Y, and Haba R. Cytopatholologic features of gliosarcoma with areas of primitive neuroepithelial differentiation of the brain in squash smears. Diagn Cytopathol 2009; 37: 906-909.
27. Helseth R, Helseth E, Johannesen TB, Langberg CW, Lote K, Ronning P, Scheie D, Vik A, and Meling TR. Overall survival, prognostic factors, and repeated surgery in a consecutive series of 516 patients with glioblastoma multiforme. Acta Neurol Scand 2010; 122: 159-167.
28. Ohgaki H and Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007; 170: 1445-1453.
29. Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, and Mirimanoff RO. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
30. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, Oh EY, Gaber MW, Finklestein D, Allen M, Frank A, Bayazitov IT, Zakharenko SS, Gajjar A, Davidoff A, and Gilbertson RJ. A perivascular niche for brain tumor stem cells. Cancer Cell 2007; 11: 69-82.
31. Gilbertson RJ and Rich JN. Making a tumour's bed: glioblastoma stem cells and the vascular niche. Nat Rev Cancer 2007; 7: 733-736.